THE ETHICS OF MEDICARE POLICY: INCREASING TRANSPLANT ACCESS AND SURVIVAL.
作者信息
Gordon Elisa J
机构信息
Ph.D., M.P.H., Assistant Professor of Bioethics and Health Policy, Neiswanger Institute for Bioethics and Health Policy, Loyola University of Chicago, Department of Medicine, Bldg. 120, Rm. 280, 2160 South First Avenue, Maywood, IL 60153; Tel: 708-327-9220;
出版信息
De Paul Law Rev. 2006 Spring;55(3):1045-1066.
Abstract
摘要
相似文献
1
THE ETHICS OF MEDICARE POLICY: INCREASING TRANSPLANT ACCESS AND SURVIVAL.医疗保险政策的伦理：增加移植机会与提高存活率
De Paul Law Rev. 2006 Spring;55(3):1045-1066.
2
Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era.在当前时代，扩大医疗保险免疫抑制药物覆盖范围以惠及肾移植受者的经济评估。
J Am Soc Nephrol. 2020 Jan;31(1):218-228. doi: 10.1681/ASN.2019070646. Epub 2019 Nov 8.
3
Transplant recipients are vulnerable to coverage denial under Medicare Part D.器官移植受者在医疗保险 D 部分下容易面临保险拒付。
Am J Transplant. 2018 Jun;18(6):1502-1509. doi: 10.1111/ajt.14703. Epub 2018 Mar 30.
4
Medicare immunosuppressant coverage and access to kidney transplantation: a retrospective national cohort study.医疗保险免疫抑制剂覆盖范围与肾移植机会：一项回顾性全国队列研究。
BMC Health Serv Res. 2012 Aug 16;12:254. doi: 10.1186/1472-6963-12-254.
5
Comparison of Evaluations for Heart Transplant Before Durable Left Ventricular Assist Device and Subsequent Receipt of Transplant at Transplant vs Nontransplant Centers.心脏移植前使用耐用性左心室辅助装置评估与在移植中心和非移植中心接受移植后的比较。
JAMA Netw Open. 2022 Nov 1;5(11):e2240646. doi: 10.1001/jamanetworkopen.2022.40646.
6
Association of Public Reporting of Medicare Dialysis Facility Quality Ratings With Access to Kidney Transplantation.医疗保险透析机构质量评级公开报告与获得肾脏移植机会的关联。
JAMA Netw Open. 2021 Sep 1;4(9):e2126719. doi: 10.1001/jamanetworkopen.2021.26719.
7
Declining Medicare reimbursement in abdominal transplantation from 2000 to 2021.2000 年至 2021 年，腹部移植 Medicare 报销费用下降。
Surgery. 2023 Jun;173(6):1484-1490. doi: 10.1016/j.surg.2023.01.015. Epub 2023 Mar 7.
8
Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant.将医疗保险对免疫抑制药物的覆盖范围延长至肾移植受者终身的成本效益。
Am J Transplant. 2004 Oct;4(10):1703-8. doi: 10.1111/j.1600-6143.2004.00565.x.
9
Now is the time for the Organ Procurement and Transplantation Network to change regulatory policy to effectively increase transplantation in the United States; Carpe Diem.现在是时候让器官获取与移植网络改变监管政策，以有效地增加美国的移植数量了；抓住时机。
Am J Transplant. 2020 Aug;20(8):2026-2029. doi: 10.1111/ajt.15759. Epub 2020 Jan 27.
10
Practice patterns in arteriovenous fistula ligation among kidney transplant recipients in the United States Renal Data Systems.美国肾脏数据系统中肾移植受者动静脉瘘结扎的实践模式。
J Vasc Surg. 2019 Sep;70(3):842-852.e1. doi: 10.1016/j.jvs.2018.11.048. Epub 2019 Mar 8.
引用本文的文献
1
Closing the gap between evidence and practice in chronic kidney disease.缩小慢性肾脏病领域证据与实践之间的差距。
Kidney Int Suppl (2011). 2017 Oct;7(2):114-121. doi: 10.1016/j.kisu.2017.07.006. Epub 2017 Sep 20.
2
Medicare immunosuppressant coverage and access to kidney transplantation: a retrospective national cohort study.医疗保险免疫抑制剂覆盖范围与肾移植机会：一项回顾性全国队列研究。
BMC Health Serv Res. 2012 Aug 16;12:254. doi: 10.1186/1472-6963-12-254.
3
Disparities in kidney transplant outcomes: a review.肾脏移植结局的差异：综述。
Semin Nephrol. 2010 Jan;30(1):81-9. doi: 10.1016/j.semnephrol.2009.10.009.
4
Ethnic advantages in kidney transplant outcomes: the Hispanic Paradox at work?肾移植结果中的种族优势：西班牙裔悖论在起作用？
Nephrol Dial Transplant. 2009 Apr;24(4):1103-9. doi: 10.1093/ndt/gfn691. Epub 2008 Dec 15.
5
The financial impact of immunosuppressant expenses on new kidney transplant recipients.免疫抑制剂费用对新肾移植受者的经济影响。
Clin Transplant. 2008 Nov-Dec;22(6):738-48. doi: 10.1111/j.1399-0012.2008.00869.x. Epub 2008 Jul 31.
Zotero 插件